Dyskinesia matters

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Levodopa-induced dyskinesia (LID) represents a significant source of discomfort for people with Parkinson's disease (PD). It negatively affects quality of life, it is associated with both motor and nonmotor fluctuations, and it brings an increased risk of disability, balance problems, and falls. Although the prevalence of severe LID appears to be lower than in previous eras (likely owing to a more conservative use of oral levodopa), we have not yet found a way to prevent the development of this complication. Advanced surgical therapies, such as deep brain stimulation, ameliorate LID, but only a minority of PD patients qualify for these interventions. Although some have argued that PD patients would rather be ON with dyskinesia than OFF, the deeper truth is that patients would very much prefer to be ON without dyskinesia. As researchers and clinicians, we should aspire to make that goal a reality. To this end, translational research on LID is to be encouraged and persistently pursued.

Detaljer

Författare
Enheter & grupper
Externa organisationer
  • Karolinska Institute
  • University of Kansas Medical Center
  • Feinstein Institute for Medical Research
  • University of South Florida
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Neurologi

Nyckelord

Originalspråkengelska
TidskriftMovement Disorders
StatusE-pub ahead of print - 2019
PublikationskategoriForskning
Peer review utfördJa